How much funding has Damora Therapeutics raised?

Damora Therapeutics has raised $284.9M in total funding, most recently a private equity round.

Who are Damora Therapeutics's investors?

Damora Therapeutics's investors include Fairmount, Viking Global.

Where is Damora Therapeutics headquartered?

Damora Therapeutics is headquartered in Boston, Massachusetts, United States.

What industry is Damora Therapeutics in?

Damora Therapeutics operates in Healthcare, Biotech.

How many employees does Damora Therapeutics have?

Damora Therapeutics has 11-50 employees.

Damora Therapeutics

IPO

Public · Boston, United States · $284.9M raised

Healthcare

Biotech

Headquarters: Boston, Massachusetts
Employees: 11–50
Business Model: B2B
Website: damoratherapeutics.com

Total Funding: $284.9M
Last Round: $284.9M Private EquityNov 2025
Rounds: 1
Type: Public

About

Damora Therapeutics is an innovative biotechnology company advancing a new generation of disease-modifying biologics to redefine care for people with hematologic disorders. The company is focused on mutant calreticulin-driven myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET) and myelofibrosis (MF). Its lead program, DMR-001, is an investigational monoclonal antibody designed to selectively target mutant calreticulin. Damora was originally founded on assets developed by Paragon Therapeutics and was acquired by Galecto, Inc. in November 2025 in a transaction valued at $285 million. In March 2026, Galecto formally changed its name to Damora Therapeutics and began trading on Nasdaq under the ticker DMRA.

Summary

Damora Therapeutics is a Healthcare company based in Boston, United States. It has raised $284.9M in total across 1 round, most recently a $284.9M Private Equity round in Nov 2025. Investors include Fairmount and Viking Global.